| BEQGX | VFINX | BEQGX / VFINX | |
| Total Expense Ratio | 0.65 | 0.14 | 464% |
| Annual Report Gross Expense Ratio | 0.65 | 0.14 | 464% |
| Fund Existence | 35 years | 50 years | - |
| Gain YTD | 13.772 | 11.097 | 124% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 2500 | 0 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 1.96B | 1.76T | 0% |
| Annual Yield % from dividends | 0.44 | 0.94 | 47% |
| Returns for 1 year | 9.29 | 15.25 | 61% |
| Returns for 3 years | 64.27 | 70.24 | 92% |
| Returns for 5 years | 10.58 | 70.38 | 15% |
| Returns for 10 years | 58.35 | 258.28 | 23% |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| EVX | 39.94 | 0.34 | +0.85% |
| VanEck Environmental Svcs ETF | |||
| XTN | 102.41 | 0.55 | +0.54% |
| State Street® SPDR® S&PTrsptnETF | |||
| RCLR | 51.67 | 0.02 | +0.04% |
| Reckoner BBB-B Clo Reinvesting ETF | |||
| CPNS | 28.33 | N/A | +0.01% |
| Calamos Nasdaq-100 Str Alt Prt ETF-Sep | |||
| IHE | 101.07 | -0.20 | -0.20% |
| iShares US Pharmaceuticals ETF | |||